| Methods |
2‐ to 4‐week washout; 10‐29 day single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐114 mm Hg after run‐in; 9‐week double‐blind treatment, patients received tasosartan 25 mg initially, this dose was titrated to 50 mg at end of week 3 and to 100 mg at end of week 6 until efficacy was achieved (defined as mean trough sitting DBP of 90 mm Hg or less or a change of 10 mm Hg or more from baseline) or the highest dose (100 mg) was reached in the absence of adverse events |
| Participants |
Tasosartan 25 mg: n=71(51 males, 20 females); mean age=53.5(8.8) years; baseline sitting SBP=154.1 mm Hg, DBP=101.2 mm Hg;
Placebo: n=71(55 males,16 females); mean age=50.9(10.5) years; baseline sitting SBP=151.5 mm Hg, DBP=101.6 mm Hg |
| Interventions |
Tasosartan 25 mg once daily;
Placebo;
taken at 8:30 AM (± 1 h) |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP |
| Notes |
Used week 3 BP data only; BP change reported; SD of change not reported; endpoint BP and SD not reported; baseline SBP/DBP SD not reported; imputed overall trial mean SD of change for SBP and DBP; BP data from Table 2, p. 296; BP measurement device not reported; WDAE reported at endpoint but not at week 3; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
